2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-149004A
    SLF1081851 TFA 2763730-98-7 98%
    SLF1081851 (TFA) is a Spns2 inhibitor, inhibits S1P release (IC50=1.93 μM). SLF1081851 (TFA) plays a key role in development and immune system.
    SLF1081851 TFA
  • HY-149004B
    SLF1081851 hydrochloride 2999629-35-3 98%
    SLF1081851 (hydrochloride) is a Spns2 inhibitor, inhibits S1P release (IC50=1.93 μM). SLF1081851 (hydrochloride) plays a key role in the development and immune system.
    SLF1081851 hydrochloride
  • HY-14956S1
    Nemonoxacin-d3-1 98%
    Nemonoxacin-d3-1 is the deuterium labeled Nemonoxacin. Nemonoxacin (TG-873870) is an orally active and potent broad-spectrum antibiotic. Nemonoxacin shows good inhibitory activity against different species of staphylococci, streptococci, and enterococci, Neisseria gonorrhoeae, and Haemophilus influenza. Nemonoxacin can be used in the study of bacterial infections and community-acquired pneumonia.
    Nemonoxacin-d3-1
  • HY-14956S2
    Nemonoxacin-d4 98%
    Nemonoxacin-d4 is the deuterium labeled Nemonoxacin. Nemonoxacin (TG-873870) is an orally active and potent broad-spectrum antibiotic. Nemonoxacin shows good inhibitory activity against different species of staphylococci, streptococci, and enterococci, Neisseria gonorrhoeae, and Haemophilus influenza. Nemonoxacin can be used in the study of bacterial infections and community-acquired pneumonia.
    Nemonoxacin-d4
  • HY-14956S3
    Nemonoxacin-13C,d3
    Nemonoxacin-13C,d3 (TG-873870-13C,d3) is the deuterium and 13C-labeled Nemonoxacin (HY-14956). Nemonoxacin (TG-873870) is an orally active and potent broad-spectrum antibiotic. Nemonoxacin shows good inhibitory activity against different species of staphylococci, streptococci, and enterococci, Neisseria gonorrhoeae, and Haemophilus influenza. Nemonoxacin can be used in the study of bacterial infections and community-acquired pneumonia.
    Nemonoxacin-13C,d3
  • HY-14956S4
    Nemonoxacin-13C,d3 dihydrochloride
    Nemonoxacin-13C,d3 dihydrochloride (TG-873870-13C,d3 dihydrochloride) is the deuterium and 13C-labeled Nemonoxacin dihydrochloride. Nemonoxacin (TG-873870) is an orally active and potent broad-spectrum antibiotic. Nemonoxacin shows good inhibitory activity against different species of staphylococci, streptococci, and enterococci, Neisseria gonorrhoeae, and Haemophilus influenza. Nemonoxacin can be used in the study of bacterial infections and community-acquired pneumonia.
    Nemonoxacin-13C,d3 dihydrochloride
  • HY-149650A
    TLR4 agonist-1 TEA 3020639-70-4 98%
    TLR4 agonist-1 (TEA) (compound 17a) is a potent agonist of Toll-like Receptor 4 (TLR4), and induces the generation of MIP-1β in RAW 264.7 and MM6 cells.
    TLR4 agonist-1 TEA
  • HY-149773S
    HPK1-IN-40-d2 3032624-35-1 98%
    HPK1-IN-40 (compound 49) is a potent and selective HPK1 inhibitor with an IC50 of 0.9 nM. HPK1-IN-40 reinvigorates T-cell receptor (TCR) signaling, promoting T-cell function and cytokine production in T cells while having anti-cancer activity.
    HPK1-IN-40-d2
  • HY-150095A
    YE6144 free base 3065657-01-1
    YE6144 free base is a selective prototypical interferon regulatory factor 5 (IRF5) inhibitor. YE6144 free base suppresses the disease course and is especially effective in remission maintenance in a mouse model of systemic lupus erythematosus (SLE). YE6144 free base can be used for SLE research.
    YE6144 free base
  • HY-150212A
    Tilsotolimod sodium 2089768-67-0
    Tilsotolimod (IMO-2125) sodium is a TLR9 agonist. Tilsotolimod sodium activates the TLR9 signaling pathway, triggers downstream pro-inflammatory and immunostimulatory pathways, enhances the uptake and killing of cancer cells, and induces adaptive immune responses. Tilsotolimod sodium is applicable to research related to melanoma and colorectal cancer.
    Tilsotolimod sodium
  • HY-150213A
    ODN BW001 sodium
    ODN BW001 sodium is an oligodeoxynucleotide (ODN). ODN BW001 sodium plays a regulatory role in the proliferation and activation of osteoblast.
    ODN BW001 sodium
  • HY-15027S2
    5-Aminosalicylic acid-13C6 1189709-96-3 98%
    5-Aminosalicylic acid-13C6 is the 13C labeled 5-Aminosalicylic Acid. 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB.
    5-Aminosalicylic acid-13C6
  • HY-15030AR
    Naproxen sodium (Standard) 26159-34-2 98%
    Naproxen (sodium) (Standard) is the analytical standard of Naproxen (sodium). This product is intended for research and analytical applications. Naproxen sodium is a COX-1 and COX-2 inhibitor with IC50s of 8.72 and 5.15 μM, respectively in cell assay.
    Naproxen sodium (Standard)
  • HY-150521R
    Hispolon (Standard) 173933-40-9
    4-Hydrazinobenzoic acid (Standard) is the analytical standard of 4-Hydrazinobenzoic acid. This product is intended for research and analytical applications. 4-Hydrazinobenzoic acid is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
    Hispolon (Standard)
  • HY-150617A
    (Rac)-Lartesertib 2020089-41-0 98%
    (Rac)-Lartesertib ((Rac)-M4076) is an isoform of Lartesertib (HY-150617). Lartesertib (M4076) is an inhibitor of the serine/threonine protein kinase ATM with high potency. Lartesertib can inhibit the growth of multiple hematopoietic cell lines. Additionally, when combined with the ATR inhibitor Tuvusertib (HY-111451), Lartesertib can promote the death of tumor cells, activate the immune signaling pathway, and exhibit anti-tumor activity.
    (Rac)-Lartesertib
  • HY-150724A
    Biotin-labeled ODN 1018 sodium
    Biotin-labeled ODN 1018 (sodium), an oligodeoxynucleotide, is a TLR-9 agonist. Biotin-labeled ODN 1018 (sodium) can be used to evaluate CpG ODN cellular uptake and localization using a biotin detection system and light microscopy.
    Biotin-labeled ODN 1018 sodium
  • HY-150725A
    Biotin-labeled ODN 1585 sodium
    Biotin-labeled ODN 1585 (sodium) is a potent inducer of IFN and TNFα production. Biotin-labeled ODN 1585 (sodium) can be used to evaluate CpG ODN cellular uptake and localization using a biotin detection system and light microscopy.
    Biotin-labeled ODN 1585 sodium
  • HY-150725B
    FITC-labeled ODN 1585 sodium
    FITC-labeled ODN 1585 (sodium) is a potent inducer of IFN and TNFα production. FITC-labeled ODN 1585 (sodium) can be used to evaluate CpG ODN cellular uptake and localization by confocal laser-scanning microscopy (excitation 495 nm, emission 520 nm) or flow cytometry.
    FITC-labeled ODN 1585 sodium
  • HY-150726A
    Biotin-labeled ODN 1668 sodium
    Biotin-labeled ODN 1668 (sodium), a class B CpG ODN (oligodeoxynucleotide), is a TLR9 agonist. Biotin-labeled ODN 1668 (sodium) can be used to evaluate CpG ODN cellular uptake and localization using a biotin detection system and light microscopy.
    Biotin-labeled ODN 1668 sodium
  • HY-150726B
    FITC-labeled ODN 1668 sodium
    FITC-labeled ODN 1668 (sodium), a class B CpG ODN (oligodeoxynucleotide), is a TLR9 agonist. FITC-labeled ODN 1668 (sodium) can be used to evaluate CpG ODN cellular uptake and localization by confocal laser-scanning microscopy (excitation 495 nm, emission 520 nm) or flow cytometry.
    FITC-labeled ODN 1668 sodium
Cat. No. Product Name / Synonyms Application Reactivity